Fourteen patients affected by metastatic colorectal cancer were subjected to alternating cycles as follows: cycle ''A'', low immunomodulating doses of Alpha-2b Interferon (IFN, 3 MIU/m(2) daily for 5 days, 1(st) week of the cycle), followed by 5-Fluorouracil (5-FU, 400 mg/m(2) iv, daily for 5 days) + Folinic acid (FA, 200 mg/m(2) iv, daily for 5 days) in the 2(nd) week, followed again by IFN in the 3(rd) week, with 1 week interval prior to the next cycle; cycle ''B'', 5-FU + FA without IFN. Hematological, biochemical and physical evaluation showed that both treatment cycles were well tolerated, However, transient fever and moderate flu-like symptoms were observed following IFN administration, and mucositis was the predominant toxicity of both types of cycle. Moreover, reduction of granulocyte and platelet counts after chemotherapy was more pronounced during cycles ''A'' than during cycles ''B''. Clinical results on 12 evaluable patients indicated a limited response rate (i.e, 1 partial remission and 8 minor responses or stable diseases). However, the relative long survival time of non-progressor patients would suggest that this protocol could be of potential value for stabilization of the disease.
TREATMENT OF ADVANCED COLORECTAL-CANCER - A PILOT CLINICAL-STUDY WITH 5-FLUOROURACIL AND FOLINIC ACID IN COMBINATION WITH INTERFERON-ALPHA
TONINI G;
1995-01-01
Abstract
Fourteen patients affected by metastatic colorectal cancer were subjected to alternating cycles as follows: cycle ''A'', low immunomodulating doses of Alpha-2b Interferon (IFN, 3 MIU/m(2) daily for 5 days, 1(st) week of the cycle), followed by 5-Fluorouracil (5-FU, 400 mg/m(2) iv, daily for 5 days) + Folinic acid (FA, 200 mg/m(2) iv, daily for 5 days) in the 2(nd) week, followed again by IFN in the 3(rd) week, with 1 week interval prior to the next cycle; cycle ''B'', 5-FU + FA without IFN. Hematological, biochemical and physical evaluation showed that both treatment cycles were well tolerated, However, transient fever and moderate flu-like symptoms were observed following IFN administration, and mucositis was the predominant toxicity of both types of cycle. Moreover, reduction of granulocyte and platelet counts after chemotherapy was more pronounced during cycles ''A'' than during cycles ''B''. Clinical results on 12 evaluable patients indicated a limited response rate (i.e, 1 partial remission and 8 minor responses or stable diseases). However, the relative long survival time of non-progressor patients would suggest that this protocol could be of potential value for stabilization of the disease.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
